The purpose of this clinical study is to evaluate the clinical effect of midodrine
hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by
measuring the time to onset of near syncopal symptoms and assessing several cardiovascular
measurements, such as heart rate, blood pressure, and ECG, using the tilt table test.
The primary objective of this study is to evaluate the effect of rufinamide on total partial
seizure frequency in adolescent and adult patients with refractory partial onset seizures
currently inadequately treated with a maximum of three stable antiepileptic medications.
Secondary objectives are to evaluate the effect of rufinamide on secondary and exploratory
outcomes, to confirm the safety profile of rufinamide, and to assess the relationship
between ... Read More
This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of
JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05
201, or ADX-N05 202.
The purpose of this study is to determine whether PXT3003 is effective and safe in the
treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will
assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated
for 15 months.
Source: National Institutes of Health Clinical Center (CC)
The purpose of this study is to assist training doctors about different diseases of the
nervous system affecting sleep.
Patients selected to participate in this study will have any of a variety of sleep
disorders. They will undergo several tests including an overnight recording of brain
activity, eye movement, leg movement, breathing, heart rate, and other measures.
Results of these tests will be used to better understand diseases causing sleep disorders
... Read More
All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary
study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be
eligible to continue in the extension study CLN-PXT3003-03.
Patients randomised to PXT3003 dose 1 or 2 in the primary study (CLN-PXT3003-02) will
continue in the extension study at the same dose, while the patients who received placebo
will be assigned to one of the two active ... Read More
This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm
parallel group study of safety and efficacy of JZP-110 in the treatment of excessive
sleepiness in adult subjects with OSA.
The purpose of the study is to document long-term response in real-life practice after
injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia
(Long-term clinical and pharmaco-economic data).
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter,
4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of
excessive sleepiness in adult subjects with narcolepsy.
Source: Sheffield Teaching Hospitals NHS Foundation Trust
This is a non-invasive study investigating whether EEG, which is used in routine clinical
care can be useful in diagnosing dementia. Novel in house developed software will analyse
EEG data for this purpose from people with Alzheimer's disease and healthy volunteers.
The purpose of this study is to evaluate the continued efficacy of modafinil treatment,
compared to placebo treatment, in children and adolescents with
attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment.
In this study, the investigators are looking at how PTSD affects things such as memory,
attention, reaction to sounds, eye movements, and heart rate. The investigators are also
studying whether a medication called prazosin has an effect on these things.